What is the molecular weight of aprotinin?
6511
4.1Computed Properties
| Property Name | Property Value |
|---|---|
| Molecular Weight | 6511 |
| XLogP3-AA | -25.4 |
| Hydrogen Bond Donor Count | 93 |
| Hydrogen Bond Acceptor Count | 97 |
What is the mechanism of aprotinin?
Mechanism of drug action Aprotinin is a competitive inhibitor of several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa.
Is aprotinin a protein?
Aprotinin is a bovine-derived protein that inhibits plasmin and multiple other human proteases.
Is aprotinin hazardous?
Although there is abundant evidence that aprotinin reduces blood loss and transfusion requirements in cardiac surgery patients, an observational study in patients undergoing elective coronary revascularization surgery revealed that aprotinin increased the risk of renal failure, myocardial infarction, heart failure.
Is aprotinin off the market?
The antifibrinolytic agent aprotinin, a naturally occurring serine protease inhibitor, was removed from the worldwide market in October 2007.
What type of inhibitor is aprotinin?
Aprotinin is an important member of a family of related protease inhibitors and has many clinically beneficial activities. These inhibitors have multiple functions, but not all of them are mediated by enzyme inhibition.
Why was aprotinin removed from the market?
Bayer has notified the FDA that it will remove all remaining stocks of Trasylol (aprotinin injection) from the U.S. market due to the final results of the BART study which showed an increased risk of death with Trasylol compared with aminocaproic acid and tranexamic acid.
How do you dissolve aprotinin?
Aprotinin: Dissolve 20 mg in 10 ml of water or PBS to get 2mg/ml stock (1000X). Working concentration is 2µg/ml, so add 1µl of stock in 1 ml of lysis buffer.
Why aprotinin is withdrawn?
The strong and consistent negative mortality trend seen with aprotinin led the investigators to suggest that its use in high-risk cardiac surgery was unwarranted despite its potential for reducing massive bleeding. Shortly after the end of the trial, Bayer voluntarily withdrew aprotinin from the market.
Is aprotinin a competitive inhibitor?
Thromb Res.
How many days should I take tranexamic acid?
Tranexamic acid is usually used for a short time to treat bleeding. Usually you will take this medicine for 4 days for heavy periods, or for 7 days to treat other bleeding that does not stop by itself.
Is it OK to take tranexamic acid for heavy periods?
Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of blood clots, which prevents bleeding.
What type of drug is aprotinin?
Aprotinin. The drug aprotinin (Trasylol, previously Bayer and now Nordic Group pharmaceuticals), is a small protein bovine pancreatic trypsin inhibitor ( BPTI ), or basic trypsin inhibitor of bovine pancreas, which is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzymes.
What does aprotinin do to trypsin?
Aprotinin is a competitive inhibitor of several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml.
What is the efficacy of aprotinin in surgery?
Drug efficacy. In cardiac surgery with a high risk of significant blood loss, aprotinin significantly reduced bleeding, mortality and hospital stay. Beneficial effects were also reported in high-risk orthopedic surgery. In liver transplantation, initial reports of benefit were overshadowed by concerns about toxicity.
How does aprotinin affect thrombin and fibrin?
Aprotinin did not affect thrombin activity, fibrin structure, platelet aggregation or secretion. Aprotinin counteracts heparin suppression of platelet force and enhances platelet force in the absence of heparin. Aprotinin- heparin -platelet interactions may help explain aprotinin’s ability to reduce blood loss during CPB.